Rabbit Polyclonal CHRFAM7A Antibody

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: Mouse heart tissue, Primary antibody: P04129(CHRFAM7A Antibody) at dilution 1/700, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P04129(CHRFAM7A Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P04129(CHRFAM7A Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The CHRFAM7A gene is a human-specific fusion gene resulting from a partial duplication of the CHRNA7 gene (encoding the α7 subunit of the nicotinic acetylcholine receptor) and a member of the FAM7A family. It produces a truncated protein, dupα7. which retains the ligand-binding domain of α7 but lacks the transmembrane region, potentially modulating cholinergic signaling. CHRFAM7A is implicated in neuropsychiatric disorders (e.g., schizophrenia, Alzheimer’s disease) and inflammatory processes, though its exact biological role remains unclear.

Antibodies targeting CHRFAM7A/dupα7 are critical tools for studying its expression, localization, and interaction partners. Due to sequence homology with CHRNA7 and alternative splicing variants, antibody specificity is a major challenge. Many commercial antibodies may cross-react with α7 or other isoforms, necessitating rigorous validation via knockout controls or epitope mapping. Research applications include immunohistochemistry, Western blotting, and flow cytometry to explore tissue distribution (e.g., brain, immune cells) and disease associations.

Recent studies highlight CHRFAM7A’s role in neuroinflammation and neuroprotection, with dupα7 potentially acting as a dominant-negative regulator of α7 nAChR function. However, inconsistent antibody performance and limited standardization have hindered consensus. Efforts to develop isoform-specific antibodies and clarify CHRFAM7A’s pathophysiological relevance remain priorities in neuroscience and immunology research.